Badescu Minerva Codruta, Butnariu Lăcrămioara Ionela, Costache Alexandru Dan, Gheorghe Liliana, Seritean Isac Petronela Nicoleta, Chetran Adriana, Leancă Sabina Andreea, Afrăsânie Irina, Duca Ștefania-Teodora, Gorduza Eusebiu Vlad, Costache Irina Iuliana, Rezus Ciprian
Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
III Internal Medicine Clinic, "St. Spiridon" County Emergency Clinical Hospital, 700111 Iasi, Romania.
Life (Basel). 2023 Jun 12;13(6):1371. doi: 10.3390/life13061371.
Factor V (FV) Leiden and prothrombin G20210A are the most common hereditary thrombophilias. While their role in venous thromboembolism is well known, there are still uncertainties regarding their relationship with arterial thrombotic events, especially coronary ones. Our research, based on an in-depth analysis of the available literature, provides up-to-date information on the relationship between FV Leiden and prothrombin G20210A and acute myocardial infarction. FV Leiden and prothrombin G20210A screening should be implemented only in select cases, such as acute coronary syndrome in young individuals and/or in the absence of traditional cardiovascular risk factors and/or in the absence of significant coronary artery stenosis at angiography. Their identification should be followed by the implementation of optimal control of modifiable traditional cardiovascular risk factors to reduce the risk of recurrent events and genotyping and genetic counseling of all family members of affected cases for proper prophylaxis. An extended dual antiplatelet therapy (DAPT) may be considered, given the lower risk of bleeding under DAPT conferred by FV Leiden.
凝血因子V(FV)Leiden突变和凝血酶原G20210A突变是最常见的遗传性易栓症。虽然它们在静脉血栓栓塞中的作用已为人熟知,但它们与动脉血栓事件,尤其是冠状动脉血栓事件之间的关系仍存在不确定性。我们的研究基于对现有文献的深入分析,提供了关于FV Leiden突变和凝血酶原G20210A突变与急性心肌梗死之间关系的最新信息。FV Leiden突变和凝血酶原G20210A突变筛查仅应在特定情况下进行,例如年轻个体的急性冠状动脉综合征和/或无传统心血管危险因素和/或血管造影时无明显冠状动脉狭窄。识别出这些突变后,应实施对可改变的传统心血管危险因素的最佳控制,以降低复发事件的风险,并对受影响病例的所有家庭成员进行基因分型和遗传咨询,以进行适当的预防。鉴于FV Leiden突变使双重抗血小板治疗(DAPT)下出血风险降低,可考虑延长DAPT治疗。